Chemotherapeutic Action of a Cyclic Nitrogen Mustard Phosphamide Ester (B 518-ASTA) in Experimental Tumours of the Rat

No abstract is available for this paper.

• Publication year

  1958

• Venue

  Nature

• Publication date

  1958-03-29

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1038/181931A0PMID 13526741
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Effect of a cyclic nitrogen mustard-phosphamidester on experimentally induced tumors in rats; chemotherapeutic effect and pharmacological properties of B 518 ASTA].

  1958cited by this paper
• [Pharmacological characterization of cyclic nitrogen mustard phosphamide esters as cancer therapeutic agents].

  1958cited by this paper
• Preparation of N-Phosphorylated Derivatives of Bis-β-chloroethylamine1a

  1954cited by this paper
• [Specific chemotherapy of carcinoma of the prostate].

  1952cited by this paper

• A density functional theory study of cyclophosphamide and purinethol adsorption on a covalent triazine framework (CTF-2) for drug delivery applications

  2026cites this paper
• NLRP3 as a therapeutic target in cyclophosphamide-associated toxicities

  2025cites this paper
• Electrochemical monitoring of immunosuppressant cyclophosphamide detection using conductive molecularly imprinted polymeric films

  2025cites this paper
• Spray-dried cyclophosphamide-loaded polyhydroxyalkanoate microparticles: design and characterization

  2024cites this paper
• Exploration of the potential causative genes for inflammatory bowel disease: Transcriptome-wide association analysis, Mendelian randomization analysis and Bayesian colocalisation

  2024cites this paper
• Phenoconversion and in vivo phenotyping of hepatic cytochrome P450: Implications in predictive precision medicine and personalized therapy

  2024cites this paper
• Tert-butylhydroquinone prevents cyclophosphamide induce lung toxicity in rats via inhibiting oxidative stress and apoptosis: in vivo and in silico study

  2024cites this paper
• Preliminary proteomic analysis of mouse lung tissue treated with cyclophosphamide and Venetin-1

  2024cites this paper
• Mechanism-of-Action-Based Development of New Cyclophosphamides

  2023cites this paper
• Bispecific Antibodies in Multiple Myeloma: Opportunities to Enhance Efficacy and Improve Safety

  2023cites this paper
• Protonated and Sodiated Cyclophosphamide Fragmentation Pathways Evaluation by Infrared Multiple Photon Dissociation Spectroscopy.

  2023cites this paper
• Ifosfamide - History, efficacy, toxicity and encephalopathy.

  2023cites this paper
• The Role of curcumin extract in Ameliorating Cyclophosphamide-Induced Cardiotoxicity

  2023cites this paper
• Insights on cyclophosphamide metabolism and anticancer mechanism of action: A computational study

  2023cites this paper
• The EZH2-H3K27me3 axis modulates aberrant transcription and apoptosis in cyclophosphamide-induced ovarian granulosa cell injury

  2023cites this paper
• Cyclophosphamide-induced seizures in a patient with neuropsychiatric systemic lupus erythematosus (NPSLE): A case report

  2023cites this paper
• Protective Effects of Antioxidants on Cyclophosphamide-Induced Ovarian Toxicity

  2022cites this paper
• The Human Milk Oligosaccharide 2'-Fucosyllactose Shows an Immune-Enhancing Effect in a Cyclophosphamide-Induced Mouse Model

  2022cites this paper
• Potential Protective Effects of Antioxidants against Cyclophosphamide-Induced Nephrotoxicity

  2022cites this paper
• Cardiotoxicity of cyclophosphamide’s metabolites: an in vitro metabolomics approach in AC16 human cardiomyocytes

  2022cites this paper
• Short-Term Intravenous Infusion of Cyclophosphamide in the Treatment of Refractory Pemphigus Vulgaris: A Retrospective Study

  2020cites this paper
• Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma

  2020cites this paper
• Visualizing semipermeability of the cell membrane using a pH-responsive ratiometric AIEgen† †Electronic supplementary information (ESI) available: Materials and methods; 1H NMR and HRMS spectra of compounds; photophysical data and imaging data. See DOI: 10.1039/d0sc02097d

  2020cites this paper
• Why Great Mitotic Inhibitors Make Poor Cancer Drugs.

  2020cites this paper
• Prodrugs activated by implantable microsystems

  2019cites this paper
• High-definition ultrasound characterization of acute cyclophosphamide-induced cystitis in the mouse

  2019cites this paper
• Lactobacillus plantarum KLDS1.0318 Ameliorates Impaired Intestinal Immunity and Metabolic Disorders in Cyclophosphamide-Treated Mice

  2019cites this paper
• Early effects of Cyclophosphamide, Methotrexate, and 5-fluorouracil on neuronal morphology and hippocampal-dependent behavior in a murine model.

  2019cites this paper
• Noninfectious Uveitis: Immunomodulatory Agents and Biologicals

  2019cites this paper
• Nitrogen Mustards As Anticancer Chemotherapies: Historic Perspective, Current Developments, And Future Trends.

  2019cites this paper
• Reduced toxicity of liposomal nitrogen mustard prodrug formulation activated by an intracellular ROS feedback mechanism in hematological neoplasm models.

  2019cites this paper
• Posterior Uveitis

  2019cites this paper
• Examination of the cellular mechanisms of leukocyte elevation by 10.6 μm and 650 nm laser acupuncture-moxibustion

  2018cites this paper
• Antineoplastic and Immunomodulating Agents (L)

  2017cites this paper
• Cyclophosphamide in dermatology

  2017cites this paper
• ANCA-Associated Vasculitis: Microscopic Polyangiitis, Eosinophilic Granulomatosis With Polyangiitis (Churg–Strauss Syndrome) and Granulomatosis With Polyangiitis (Wegener’s Granulomatosis)

  2017cites this paper
• Low dose cyclophosphamide: Mechanisms of T cell modulation.

  2016cites this paper
• Alkylating Anticancer Drugs

  2016cites this paper
• Fulminating Hemorrhagic Cystitis: New Trends from Etiology to Treatment

  2015cites this paper
• Chapter 28 – Designing Prodrugs and Bioprecursors

  2015cites this paper
• State of the Art in the Treatment of Systemic Vasculitides

  2014cites this paper
• Cystitis: From Urothelial Cell Biology to Clinical Applications

  2014cites this paper
• Immunotherapy of HPV infection-caused genital warts using low dose cyclophosphamide

  2014cites this paper
• DNA Damaging Drugs

  2014cites this paper
• Cytochrome P450 Activation of Toxins and Hepatotoxicity

  2013cites this paper
• ANÁLISE IMUNO-FENOTÍPICA DE ANIMAIS NOD: ESTUDO DA PROTEÇÃO AO DIABETES TIPO I MEDIADA PELO T. cruzi E DA INDUÇÃO PELA CICLOFOSFAMIDA.

  2013cites this paper
• Chapter 1 Conventional Cancer Treatment

  2013cites this paper
• Conventional Cancer Treatment

  2013cites this paper
• A short history of anti-rheumatic therapy VIII . The immunosuppressants

  2012cites this paper
• Ashorthistoryofanti-rheumatictherapy VIII.Theimmunosuppressants

  2012cites this paper
• The glycine deportation system and its pharmacological consequences.

  2012cites this paper
• Cyclophosphamide inhibits the generation and function of CD8(+) regulatory T cells.

  2012cites this paper
• A short story of anti-rheumatic therapy. VIII. The immunodepressants.

  2012cites this paper
• Comparative metabolism of cyclophosphamide and ifosfamide in the mouse using UPLC-ESI-QTOFMS-based metabolomics.

  2010cites this paper
• Xenobiotic metabolism: a view through the metabolometer.

  2010cites this paper
• Antineoplastic Agents, 1. Nonhormonal

  2010cites this paper
• Cobalt(II)-catalyzed intramolecular C-H amination with phosphoryl azides: formation of 6- and 7-membered cyclophosphoramidates.

  2010cites this paper
• Cyclophosphamide and cancer: golden anniversary

  2009cites this paper
• Other Forms of Immunosuppression

  2009cites this paper
• Urological implications of cyclophosphamide and ifosfamide

  2008cites this paper
• Efficient and divergent synthesis of cyclophosphamide analogues from 2-arylamino-3-acetyl-5,6-dihydro-4H-pyrans.

  2008cites this paper
• Designing Prodrugs and Bioprecursors

  2008cites this paper
• Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide.

  2008cites this paper
• Detection of donor cells in recipient tissues after stem cell transplantation using FISH and immunophenotyping

  2007cites this paper
• Dissecting the impact of chemotherapy on the human hair follicle: a pragmatic in vitro assay for studying the pathogenesis and potential management of hair follicle dystrophy.

  2007cites this paper
• The Teratogenicity of Cyclophosphamide in Mice 1-2

  2006cites this paper
• Drugs Discovered through Serendipity in the Laboratory

  2006cites this paper
• Intramolecular hydrogen bonds in crystals of thiophosphorylbenzopyrane derivatives : X-ray and FT-IR studies

  2006cites this paper
• The Teratogenicity of Cyclophosphamide in Mice1-2

  2006cites this paper
• Effects of Dosage, Phénobarbital,and 2-Diethylaminoethyl-2,2-diphen\ balenate on the Binding of Cyclophosphamide and/or Its Metabolites to the DNA, R N A, and Protein of the Embryo and Liver in Pregnant Mice1

  2006cites this paper
• Synthesis of 2‐[(2‐chloro‐2′‐[18F]fluoroethyl)amino]‐2H‐1,3,2‐oxazaphosphorinane‐2‐oxide (18F‐fluorocyclophosphamide), a potential tracer for breast tumor prognostic imaging with PET

  2005cites this paper
• Experimentelle Beiträge zur Lenkung der Organentwicklung, des Häutungsrhythmus und der Metamorphose bei der SchabePeriplaneta americana L.

  2004cites this paper
• QSAR studies of 2-substituted 2,3-dihydro-1h-naphtho[1,8-de]-1,3,2-diazaphosphorine 2-oxides and sulphides

  2004cites this paper
• Nitrogen mustards derived from diazaphosphole-2-oxide

  2004cites this paper
• Synthesis of 3-(substituted)-2,4,8,15-tetroxa-3-phosphadispiro[5.2.5]hexadecane-3-oxides

  2004cites this paper
• Nitrobenzocyclophosphamides as potential prodrugs for bioreductive activation: synthesis, stability, enzymatic reduction, and antiproliferative activity in cell culture.

  2003cites this paper
• Tumor acidity, ion trapping and chemotherapeutics. I. Acid pH affects the distribution of chemotherapeutic agents in vitro.

  2003cites this paper
• Synthesis and spectral studies (see abstract)

  2002cites this paper
• The clinical pharmacology of alkylating agents in high-dose chemotherapy.

  2000cites this paper
• Syntheses and Antimicrobial Activity of 2-Substituted-2,3-Dihydro-3-(4′-Bromophenyl)-1H-Naphth[1,2-e][1,3,2]Oxazaphosphorin 2-Oxides/Sulfides

  2000cites this paper
• Phosphoramide and Oxazaphosphorine Mustards

  1997cites this paper
• Cyclophosphamide-induced aberrations of chromosome pairing in pachytene oocytes.

  1997cites this paper
• The history of the oxazaphosphorine cytostatics

  1996cites this paper
• Stereospecific synthesis of tetradeuterated (R)‐ and (S)‐ifosfamide

  1996cites this paper
• The effect of cyclophosphamide on rat blastocysts in vitro and their subsequent development following transfer to pseudopregnant rats.

  1996cites this paper
• The therapeutic effect of a combination of cofpropamine, a caffeine derivative, and cyclophosphamide on the development of adjuvant arthritis of rats and collagen arthritis of mice.

  1996cites this paper
• Identification of new metabolites of ifosfamide in rat urine using ion cluster technique

  1995cites this paper
• Collaborative assessment of optimal administration period and parameters to detect effects on male fertility in the rat: effects of cyclophosphamide on the male reproductive system.

  1995cites this paper
• Toxicity of ifosfamide, cyclophosphamide and their metabolites in renal tubular cells in culture

  1994cites this paper
• Pharmacokinetics of alkylating agents.

  1993cites this paper
• A comparative analysis of the characteristics and function of naturally occurring and drug-induced natural suppressor cells in mice.

  1993cites this paper
• Enzymatic detoxification of phosphoramide mustard by soluble fractions from rat organ tissues.

  1991cites this paper
• Cyclophosphamide Toxicity

  1991cites this paper
• Cyclophosphamide toxicity. Characterising and avoiding the problem.

  1991cites this paper
• Antineoplastic Drugs in 1990

  1990cites this paper
• Antineoplastic Drugs in 1990

  1990cites this paper
• Antineoplastic drugs in 1990. A review (Part II).

  1990cites this paper
• Pharmacokinetic determinants of the activity and toxicity of antitumour agents.

  1989cites this paper
• Metabolism of oxazaphosphorines.

  1988cites this paper
• 13C and 31P NMR data for some 6‐aryloxydibenzo[d, f][1,3,2] dioxaphosphepin 6‐oxides/sulphides and 3‐cyclohexyl‐6‐(1, 1‐dimethylethyl)‐3, 4‐dihydro‐2‐aryloxy‐2h‐1,3,2‐benz‐oxazaphosphorine 2‐oxides

  1988cites this paper